Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 31, 2019 (7 years ago)

ZYFLO CR (zileuton)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications: Out of specification result for dissolution.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

ZYFLO CR (zileuton) extended-release tablets, 600 mg, 120-count bottles, Rx only, Distributed by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-902-12.

Affected NDC 10122-0902-12

Compare with the code on your package — it is the most precise check available.

Drug: Zileuton

Recalling firm
Chiesi USA, Inc.
NDC code
10122-902-12
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1341-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zileuton recalls

See all
Class II · Moderate risk

Zileuton Extended-Release Tablets

Failed Dissolution Specifications: Out of specification test results observed in dissolution testing during long term stability study.

Terminated Dissolution failure Lupin Pharmaceuticals Inc. NDC 68180-169-16 D-1150-2022

Other recalls by Chiesi USA, Inc.

All 2019 recalls
Class III · Low risk

Revcovi (elapegademase-lvlr)

Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

Ongoing Stability / shelf life Chiesi USA, Inc. NDC 10122-502-01 D-0838-2026